The first patient to have pig islet cells transplanted as part of LCT’s Diabacell clinical trials, has been able to reduce the amount of insulin he has to take daily.
An excerpt: (read in full here)
“The clinical trials of the Living Cell Technologies product – pig islet cells wrapped in a seaweed-based gelatine to stop them triggering rejection by the body’s immune system – follow trials at lower dosage rates of the Diabecell implants in Russia.
“The hospital’s centre for clinical research and effective practice said the man had suffered type 1 diabetes for 20 years but had started to drop his daily insulin injections by 30 per cent while maintaining his usual blood glucose levels.”